Diversity measures for enhancing ADME admissibility of combinatorial libraries.
For general screening libraries, structural diversity descriptors and drug-likeness indicators still do not guarantee the in vivo bioavailability for the candidates, which is considered a major bottleneck in drug development. Early prediction of pharmacokinetics (log P, log D), metabolism, and toxicity makes it possible to deal with ADME (adsorption, distribution, metabolism, excretion) related diversity as an extension to the classical diversity concepts. It opens several new possibilities for optimization of a discovery library before doing any experimental screening. This new diversity concept is demonstrated on a subset of MeDiverse, which is a diverse collection of pharmacologically relevant compounds selected from our in-house library. From consideration of the ADME interface in living systems, virtual secondary libraries of metabolites and retrometabolites (prodrugs) can be generated. These additional libraries readily enhance both the structural and ADME related diversity. This new opportunity in library design can substantially improve the success rate for in vivo lead generation from in vitro hits.